Pierre Socha
Principal
Pierre joined Amadeus Capital Partners in 2012. Pierre has a current investment focus on digital health, medical technology, AI and machine learning and cybersecurity. He is a non-executive director on the boards of Inotec, Repositive, Doctify, Congenica and oversees Amadeus’s investments in PhoreMost, Organox and Antidote (formerly TrialReach).
Pierre brings operational experience to these investments, having managed the growth of several life science businesses in Asia and Europe. During a decade at biotech company Avesthagen, he guided the group’s strategy and European activities, contributing to acquisitions, joint ventures and exits.
Pierre started his career as an auditor with KPMG in France and subsequently worked as a financial engineer at Natixis and as a research fellow in health and urban microeconomics.
Pierre is French and holds an MSc in Environmental Economics (Hons.-SciencesEco) from Université de Provence, France and a BSc in Finance & Econometrics (Math Spe.-SciencesEco) from Université Louis Pasteur, France. He has attended executive programs at Harvard, MIT and Stanford.
Pierre speaks French and English and understands German.
Pierre is the Amadeus contact for
Meet Pierre at:
25th February 2020
Super Return – Healthcare Summit
Pierre Socha will be speaking on a panel at the Healthcare Summit at the Super Return Conference in Berlin. The Healthcare Summit focuses on the role of PE in the health and social care sectors and analyses the key trends and challenges facing investors and operators. Bringing together the international healthcare investment community, including GPs, LPs and healthcare service providers, plus representatives from medical device companies, technology and healthcare IT firms and healthcare insurance providers.
13th May 2020
European Wound Management Association Annual Conference
Pierre Socha will be attending the annual European Wound Management Association Conference (EWMA) in London. The EWMA Conference is organised in cooperation with Tissue Viability Society (TVS) and offers high-level scientific presentations, networking activities and an excellent opportunity to exchange knowledge and experience with international colleagues.
More from Pierre
Blog: 9th January 2020
The Future of Cell and Gene Therapy Manufacturing Just Got Brighter
Blog: 18th December 2019
Entrepreneurs make the best tech VCs, or do they?
Blog: 23rd May 2017
Genomics: Live Long & Federate!
Blog: 24th February 2017
Genomics | Reaching Base Camp
